The global biotechnology reagents market is anticipated to witness growth over the forecast period. Biotechnology reagents are used in research fields of genetics, molecular biology, diagnosis, immunology, bioscience, and in education. Biotechnology reagents industry depends on the growth of biotechnology instrumentation market. Increasing research and development expenditure by biotechnology companies and rising number of biotechnology firms globally are expected to boost the market over the forecast period. Increasing use of biotechnology reagents in therapeutics, basic research, and its commercialization are the factors responsible for the growth of this market. Continuous product development in industries like pharmaceuticals, food and beverages, and agribiotech are expected to drive the market growth during the forecast period. Presence of novel techniques such as DNA chips, combinatorial chemistry, proteomics and high throughput screening expected to increase the market share due to increasing usage rates of reagents. Key market trends such as advancement in stem cell research and growing biomedical research activities are also anticipated to impact positively on the growth of this market. In biomedical research, reagents are use for enhancing the reaction or labeling the DNA molecules. In stem cell research reagents are used as biomarker or for dissociation of human embryonic stem cell.
Biotechnology reagents market is segmented on the basis of application, product, and technology. Various application of biotechnology reagents are fluorescent microscopy, DNA analysis, immunophenotyping, and cell cycle analysis. Products are segmented as DNA sequencing reagents, electrophoresis reagents, flow cytometry regents, immune assay, liquid chromatography, polymerase chain reagents, cell/tissue culture reagents, and protein synthesis reagents. Chromatography reagents and tissue culture reagents are expected to witness lucrative growth over the forecast period due to innovations in biotechnology industry. Biotechnology reagents market includes technologies such as IVD, PCR, transfection, gene expression and cell culture. On the basis of technology market is segmented into analytical reagents and life science reagents. Life science technologies include in vitro diagnostics, cell culture, polymerase chain reaction, and analytical technologies includes flow cytometry, electrophoresis, mass spectrometry and chromatography. Life science reagent market held the largest share in 2014 owing to the presence of high demand from life science industries due to new product developments and increasing R&D expenditure by biotech companies.
Geographically market is segmented into North America, Europe, Asia pacific, Latin America and Middle East and Africa. North America dominated the overall market in 2014 due to high investments, new product developments, presence of favorable government policies and sophisticated healthcare infrastructure. Success of human genome project and excessive demand for reagents in molecular biology sector drives the growth in the U.S. market. Asia Pacific is expected to show a lucrative growth rate during the forecast period due to increasing research and outsourcing activities in life science field.
Key market players in biotechnology reagents market are Thermo Fisher Scientific Inc., Sigma-Aldrich, Bio-Rad Laboratories, F. Hoffmann-La Roche, Agilent Technologies Inc., Water Corporation, Betcon Dickinson, Abbott, Beckman Coulterand and Life Technologies. Bio-Rad Laboratories are one of the largest PCR reagent kit providers.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPA norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.